KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Long-Term Investments: 2021-2025

  • Twist Bioscience's Long-Term Investments rose 3463.08% to $54.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $54.3 million, marking a year-over-year increase of 3463.08%. This contributed to the annual value of $54.3 million for FY2025, which is 3463.08% up from last year.
  • Latest data reveals that Twist Bioscience reported Long-Term Investments of $54.3 million as of Q3 2025, which was down 0.00% from $54.3 million recorded in Q2 2025.
  • In the past 5 years, Twist Bioscience's Long-Term Investments registered a high of $106.8 million during Q4 2021, and its lowest value of $1.5 million during Q3 2024.
  • Moreover, its 2-year median value for Long-Term Investments was $54.3 million (2025), whereas its average is $36.7 million.
  • Data for Twist Bioscience's Long-Term Investments shows a peak YoY surged of 3,463.08% (in 2025) over the last 5 years.
  • Twist Bioscience's Long-Term Investments (Quarterly) stood at $106.8 million in 2021, then reached $30.6 million in 2022, then reached $1.5 million in 2024, then spiked by 3,463.08% to $54.3 million in 2025.
  • Its Long-Term Investments stands at $54.3 million for Q3 2025, versus $54.3 million for Q2 2025 and $1.5 million for Q3 2024.